← ANALYST RATINGS · TIPRANKS
Protalix (PLX): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $12.00, the highest $12.00, the lowest $12.00. The average is +358.0% from the last price of $2.62.
Analyst ratings 1
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $2.50−16.7% | Hold | −4.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $3.00+20.0% | Hold | +14.5% | Reiterated | 13.10.26on TipRanks Oct 12 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $2.50−16.7% | Hold | −4.6% | Reiterated | 11.10.26on TipRanks Oct 10 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $3.00+20.0% | Hold | +14.5% | Reiterated | 05.10.26on TipRanks Oct 4 23:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 | Buy | +14.5% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 | Buy | +14.5% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 | Hold | +14.5% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $2.50−16.7% | Hold | −4.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 | Buy | +14.5% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 | Buy | +14.5% | Upgrade | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $12.00 | Buy | +358.0% | Reiterated | 09.09.26on TipRanks 11:15 | +1.2%next day +2.8% · 5 days +1.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Protalix
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $12.00 at a price of $2.76 (+334.8%); now: $12.00 at $2.62 (+358.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 1 | 1 | 0 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.02 (from $-0.05 to $0.01). Last quarter: $0.05.
Sales
Next quarter’s sales estimate — $12M (from $12M to $13M). Last quarter: $20M.
Best top-analyst consensus in the sector · Healthcare
About Protalix
- CEO: Dror Bashan
- Employees: 226
- 2 University Plaza, Hackensack, NJ, 07601, US
- www.protalix.com
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Data from the stock’s TipRanks forecast page, read 74 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗